1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Qualitative assessment of patients with brain tumors: intraindividual comparison of 0.1-mmol/kg gadobenate and 0.1-mmol/kg gadoterate^{^a}
Diagnostic Information End Point Reader Gadobenate Preferred No Difference Gadoterate Preferred Significance (P Value)^{^b} 3-Reader Agreement κ Value (% Agreement)
Global diagnostic preference 1 31 (49.2%) 31 (49.2%) 1 (1.6%) <.0001 0.273 (50.8%)
2 51 (82.3%) 9 (14.5%) 2 (3.2%) <.0001
3 43 (69.4%) 17 (27.4%) 2 (3.2%) <.0001
Lesion-border delineation 1 29 (46.0%) 33 (52.4%) 1 (1.6%) <.0001 0.271 (44.3%)
2 34 (54.8%) 27 (43.5%) 1 (1.6%) <.0001
3 25 (40.3%) 35 (56.5%) 2 (3.2%) <.0001
Definition of disease extent 1 15 (23.8%) 48 (76.2%) 0 <.0001 0.286 (57.4%)
2 18 (29.0%) 43 (69.4%) 1 (1.6%) <.0001
3 15 (24.2%) 45 (72.6%) 2 (3.2%) .0023
Visualization of lesion internal morphology 1 10 (15.9%) 53 (84.2%) 0 .002 0.215 (54.1%)
2 14 (22.6%) 48 (77.4%) 0 .0001
3 23 (37.1%) 38 (61.3%) 1 (1.6%) <.0001
Lesion contrast enhancement 1 31 (49.2%) 31 (49.2%) 1 (1.6%) <.0001 0.249 (49.2%)
2 51 (82.3%) 9 (14.5%) 2 (3.2%) <.0001
3 43 (69.4%) 17 (27.4%) 2 (3.2%) <.0001
↵a Comparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n = 63 for reader 1, n = 62 for readers 2 and 3. Numbers in parentheses, except where noted, represent proportions of patients.
↵b Wilcoxon signed rank test.